Insys files for bankruptcy after $225M settlement
By 
Jaclyn Jaeger2019-06-10T18:42:00
Opioid maker Insys Therapeutics has filed for bankruptcy after agreeing to a $225 million global resolution to settle investigations concerning deceptive marketing and distribution of the drug Subsys.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleRare OIG Special Fraud Alert cautions the use of speaker programs
In a rare move, the U.S. Department of Health and Human Services’ Office of Inspector General issued a Special Fraud Alert warning of inherent fraud and abuse risks associated with speaker programs.
-
ArticleMallinckrodt to pay $15.4M over kickback allegations
Pharmaceutical company Mallinckrodt is set to pay $15.4 million to the Justice Department to resolve allegations of illegal kickbacks to doctors in the form of lavish dinners and entertainment.
-
News BriefEU regulator questions 'culture of compliance' with Digital Markets Act at Apple, Google
The European Commission released its preliminary findings last week regarding Apple and Google not complying with the Digital Markets Act. It issued orders to both companies regarding their business practice and plans to release all of its findings next week.
More from Regulatory Enforcement
-
News BriefTreasury reversal of OFAC sanctions against Tornado Cash signals eroding AML scrutiny
The U.S. Treasury Department lifted its sanctions against cryptocurrency mixer Tornado Cash on Friday after a federal appeals court ruled in November the penalty levied by the agency’s Office of Foreign Assets Control was an overreach.
-
PremiumRTX and Raytheon: A case study in juggling four compliance monitors
In October 2024, aerospace and defense company Raytheon and parent company RTX reached a $950 million settlement with U.S. government agencies to resolve multiple federal law violations. More significant than the criminal penalties were the four compliance monitorships that came with the agreements.
-
News BriefCCO who was ‘sole person controlling’ investment firm charged with recidivist concentration violations
An investment company and its founder, president, and chief compliance officer flagrantly kept violating mutual fund rules for multiple years after settling with the Securities and Exchange Commission, the SEC said in a complaint against the company.